KPIs & Operating Metrics(New)

Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Asset Writedowns and Impairment Asset Writedowns and Impairment Beginning Cash Balance Beginning Cash Balance Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Cash from Restructuring Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Dividends Paid - Common Dividends Paid - Common Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt issuances

Daily Values

Growth Metrics

Amneal Pharmaceuticals (AMRX) Short-Term Debt issuances (2017 - 2025)

Amneal Pharmaceuticals has reported Short-Term Debt issuances over the past 7 years, most recently at $218.0 million for Q1 2025.

For Q1 2025, Short-Term Debt issuances rose 354.17% year-over-year to $218.0 million; the TTM value through Dec 2025 reached $218.0 million, up 354.17%, while the annual FY2025 figure was $218.0 million, 354.17% up from the prior year.
Short-Term Debt issuances for Q1 2025 was $218.0 million at Amneal Pharmaceuticals, up from $48.0 million in the prior quarter.
Over five years, Short-Term Debt issuances peaked at $218.0 million in Q1 2025 and troughed at $10.0 million in Q3 2023.
A 4-year average of $81.4 million and a median of $80.0 million in 2023 define the central range for Short-Term Debt issuances.
Biggest five-year swings in Short-Term Debt issuances: crashed 76.47% in 2023 and later surged 354.17% in 2025.
Year by year, Short-Term Debt issuances stood at $85.0 million in 2022, then increased by 28.24% to $109.0 million in 2023, then plummeted by 55.96% to $48.0 million in 2024, then surged by 354.17% to $218.0 million in 2025.
Business Quant data shows Short-Term Debt issuances for AMRX at $218.0 million in Q1 2025, $48.0 million in Q1 2024, and $109.0 million in Q4 2023.